Time BioVentures — 2026 Investments

1 investments dated 2026 · listed companies and verified rows first · show all

Waypoint Biowaypointbio.com in 𝕏Jun 2026

Waypoint Bio uses artificial intelligence, computer vision, and pooled screening to conduct deep phenotyping across thousands of cell therapy designs, enabling the discovery and optimization of superior cell therapy candidates for development.

AI & Machine LearningBiotechDeep Tech

Xinchen Wang, Ph.D.(Co-founder & CEO)David Phizicky, Ph.D.(Co-founder & CSO)Xinchen Wang(Founder)in

Co-investorsAmplify Partners Fifty Years Hummingbird Ventures MBX Capital Mitsui Global Investment Recode Ventures +3 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.